|
Administration
May be taken with or without food.
|
|
Contraindications
Severe hypertension or coronary artery disease. Children <12 years. Concomitant or within 2 weeks of MAOI therapy.
|
|
Special Precautions
Patients with CV disease (e.g. hypertension, ischaemic heart disease), diabetes mellitus, increased intraocular pressure or angle-closure glaucoma, prostatic hyperplasia or urinary obstruction, seizure disorder, thyroid dysfunction. Mild to moderate renal and severe hepatic impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor relief of congestion, cardiac and CNS changes prior and during therapy.
|
|
Adverse Reactions
Significant: Severe skin reactions (e.g. acute generalised exanthematous pustulosis).
Cardiac disorders: Tachycardia, arrhythmia, palpitation.
Eye disorders: Angle-closure glaucoma.
Gastrointestinal disorders: Dry mouth, nausea, vomiting.
Nervous system disorders: Restlessness, tremors, headache, dizziness.
Psychiatric disorders: Insomnia, sleep disturbances, anxiety, nervousness. Rarely, hallucinations (children).
Renal and urinary disorders: Urinary retention.
Skin and subcutaneous tissue disorders: Skin rashes.
Vascular disorders: Hypertension.
|
|
Drug Interactions
May increase blood pressure with TCAs, other sympathomimetic agents (e.g. decongestants, appetite suppressants, amphetamine-like psychostimulants). May partially reverse the hypotensive effect of methyldopa, α- and β-blockers, bretylium, bethanidine, guanethidine, and debrisoquine. Elimination of pseudoephedrine may be enhanced by urinary acidifiers and decreased by urinary alkalinisers.
|
|
CIMS Class
|
|
ATC Classification
R01BA02 - pseudoephedrine ; Belongs to the class of systemic sympathomimetic preparations used as nasal decongestants.
|
Sign Out
